Equities research analysts at Credit Suisse started coverage on shares of Alkermes Plc (NASDAQ:ALKS) in a research note issued to investors on Wednesday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating and a $57.00 price target on the stock. Credit Suisse’s target price indicates a potential upside of 28.29% from the company’s current price. Alkermes Plc (NASDAQ:ALKS) shares after opening at $44.68 moved to $44.79 on last trade day and at the end of the day closed at $41.53. Company price to sales ratio in past twelve months was calculated as 10.04 and price to cash ratio as 16.53. Alkermes Plc (NASDAQ:ALKS) showed a negative weekly performance of -1.05%.
athenahealth (NASDAQ:ATHN) CEO Jonathan Bush unloaded 1,000 shares of the company’s stock on the open market in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $161.74, for a total transaction of $161,740.00. Following the completion of the sale, the chief executive officer now directly owns 311,234 shares of the company’s stock, valued at approximately $50,338,987. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. athenahealth, Inc (NASDAQ:ATHN) shares fell -11.02% in last trading session and ended the day on $147.16. ATHN return on equity ratio is recorded as 0.70% and its return on assets is 0.40%. athenahealth, Inc (NASDAQ:ATHN) yearly performance is 11.34%.
Interactive Brokers Group, Inc. (NASDAQ GS:IBKR) is the first online broker to offer direct access to IEX to its investors, traders and institutions. IEX is an ATS designed to focus on investor protection and performance. Interactive Brokers Group, Inc. (NASDAQ:IBKR) shares moved down -4.53% in last trading session and was closed at $21.52, while trading in range of $20.35-$22.55. Interactive Brokers Group, Inc. (NASDAQ:IBKR) year to date performance is -11.18%.
Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) announced the pricing of underwritten public offering of one million shares of its common stock at a public offering price of $320.00 per share.In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 150,000 shares of common stock.Intercept Pharmaceuticals Inc (NASDAQ:ICPT) weekly performance is -8.40%. On last trading day company shares ended up $290.89. Intercept Pharmaceuticals Inc (NASDAQ:ICPT) distance from 50-day simple moving average is -20.83%. Analysts mean target price for the company is $546.60.
Leave a Reply